Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

New combination treatment for COPD available in primary care

  • 1 Comment

A new once-daily dual bronchodilator is now available across England for the treatment of chronic obstructive pulmonary disease, its manufacturers have announced.

Umeclidinium/vilanterol (Anoro/Ellipta) is now available to prescribe by healthcare professionals in primary care as well as secondary care in England, following a phased roll out.

The treatment, manufactured by GlaxoSmithKline and Theravance, is indicated in the UK as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.

It is a combination of two bronchodilators in a single dry powder inhaler, containing the long-acting muscarinic antagonist umeclidinium and the long-acting beta2 agonist vilanterol.

In a clinical study 98% of COPD patients were able to use the device correctly the first time following instruction and 98-99% of patients could still use it correctly six weeks later, according to the manufacturers.

The approved dose is 55/22mcg. It was granted marketing authorisation by the European Commission in May 2014.

Since July 2014 there has been a phased introduction, with availability initially limited to secondary care healthcare professionals to allow for local formulary applications.

  • 1 Comment

Readers' comments (1)

  • Do not click on the green hyperlink to Professionals on this page (above) as it takes you to a Loreal advertisement and is nothing at all to do with COPD!

    Unsuitable or offensive? Report this comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs